Avalon Globocare Corp Stock Price, News & Analysis

Avalon GloboCare Corp. (NASDAQ: ALBT) announced a substantial future cash flow expectation due to a 40% profit-sharing agreement with Laboratory Services MSO (LSM). In 2022, LSM reported significant financials: $14.7 million in revenue, $8.1 million gross profit, $2.4 million in operating expenses, and a net income of $6.3 million. Avalon acquired a 40% interest in LSM in February 2023, which enhances its strategic position in the laboratory services market. The company's growth strategy focuses on leveraging LSM's expertise in the fragmented laboratory testing space and aims to generate synergies through targeted acquisitions. Avalon also highlights LSM's strong customer service reputation, rapid turnaround times, and diverse test offerings as key competitive advantages.

Avalon GloboCare Corp. (NASDAQ: ALBT) announced the commercial launch of the KetoAir™ breathalyzer at the KetoCon Austin 2023 conference, held from April 21-23, 2023. The KetoAir™ device, which is registered with the FDA, functions as a companion diagnostic and monitoring tool for ketogenic dietary management, combining AI nutritionist consultations. Avalon has partnered with Qi Diagnostics for exclusive distribution in North America, South America, the U.K., and the EU. The initial target markets include diabetes reversal and obesity management due to the efficacy of the ketogenic diet. KetoAir™ is touted as the first breathalyzer of its kind that uses AI and a nanosensor for monitoring keto health, allowing users to track their dietary plans and receive personalized recommendations via the KetoAir app.

Avalon GloboCare Corp. (NASDAQ: ALBT) recently announced an agreement with Qi Diagnostics for exclusive distribution rights to the KetoAir™ breathalyzer in North America, South America, the U.K., and the EU. This device is aimed at the diabetes reversal and weight management markets, and combines AI nutritionist consultations with a nanosensor-based breathalyzer to monitor ketogenic dietary management. The FDA has approved KetoAir™, and Avalon plans to commercialize the product, which is backed by clinical evidence supporting nutritional ketosis for diabetes treatment. Additionally, both companies will collaborate on a lung cancer breathalyzer, sharing ownership of any resulting intellectual property. While the initial agreement is promising, a definitive agreement regarding terms and pricing is still pending.

Avalon GloboCare Corp. (NASDAQ: ALBT), a key player in cell-based technology, announced participation in the 35th Annual Roth Conference on March 13-14, 2023, held at The Ritz Carlton, Laguna Niguel in Dana Point, California. Luisa Ingargiola, Chief Financial Officer, will host one-on-one and small group meetings for investors.

The conference serves as a platform for Avalon to showcase its innovative cellular therapeutics and precision diagnostics. Investors interested in meetings can email oneononerequests@roth.com.

Avalon GloboCare Corp. (NASDAQ: ALBT) announced the acquisition of a 40% stake in Laboratory Services MSO, LLC for $21 million. The deal includes $9 million in cash, $11 million in Series B preferred stock, and $1 million due in 2024. The preferred shares will be restricted for 12 months and are subject to a leak-out provision. LSM is known for its diagnostic tests across various areas and has conducted over 600,000 tests. Avalon anticipates this transaction will boost earnings and enhance its portfolio. An exclusive option allows Avalon to acquire an additional 20% of LSM within nine months for $6 million in cash and additional shares.

Avalon GloboCare Corp. (NASDAQ: ALBT) announced the issuance of U.S. Patent No. 11,555,060 by the USPTO, covering the QTY Code, a breakthrough technology transforming water-insoluble proteins into soluble forms. This patent strengthens Avalon's intellectual property in immuno-oncology and cellular therapies, enhancing its competitive edge. The QTY platform has significant potential for applications, including addressing cytokine storms from COVID-19 and improving CAR T-cell therapies. Avalon has filed 16 joint patent applications with prestigious partners like MIT and aims to lead in innovative biotechnology solutions.

Avalon GloboCare Corp. (NASDAQ: ALBT) announced the appointment of Lourdes Felix to its Board of Directors, effective January 11, 2023. Felix, an experienced entrepreneur and corporate finance executive, has over 30 years in capital markets and public accounting. She is the CEO and CFO of BioCorRx Inc., where she has led significant capital procurement and business restructuring in the addiction treatment sector. Avalon aims to leverage her expertise to implement a roll-up strategy targeting toxicology labs within the addiction market, enhancing corporate governance and growth prospects.

Avalon GloboCare Corp. (NASDAQ: ALBT) announced a breakthrough in leukemia patient management through a newly developed fusion gene map technology. This advancement aims to create companion diagnostic kits to improve personalized treatment options. With a database from over 1,000 leukemia patients, significant unknown fusion genes were identified that may serve as diagnostic and therapeutic targets. The first diagnostic prototype is set to enter clinical studies by Q3 2023, enhancing Avalon's R&D pipeline and IP portfolio.

Avalon GloboCare Corp. (NASDAQ: ALBT) announced the completion of a $4 million private placement of Series A preferred stock with Chairman Daniel Lu. This funding, along with a previous $5 million placement, aims to finance the acquisition of Laboratory Services MSO, LLC. The acquisition is expected to close within 30 days and will enhance Avalon’s revenue and cash flow. The preferred stock is convertible into common stock at $1.00 or 90% of the closing price. An additional $6 million is planned through further stock sales for the acquisition's completion.